LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jing Yang(Zhengzhou University), Ou Jiang(Fox Chase Cancer Center), J. Wang, Ran Zhang, Jiuwei Cui(Jilin University), Gang Wu(Hubei University of Chinese Medicine), Mengmeng Qin, Q. Wang, M. Chen(Zhejiang Cancer Hospital), Qing Zhou(Jiangnan University), Cheng Huang(Army Medical University), A. Liu(Nanchang University), Q. Lin(Tongji University), J. Chang(Fudan University Shanghai Cancer Center), Desheng Hu(Union Hospital), Yu‐Fan Cheng(Shanghai Medical College of Fudan University), Ning Cui
Annals of Oncology
September 1, 2021
10.1016/j.annonc.2021.08.2122
Cited by 6

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k